Screener
Crinetics Pharmaceuticals CRNX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | Three months ended / March 31, 2026 | Three months ended / March 31, 2025 |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net loss | $(127,845) | $(96,774) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 29,680 | 20,478 |
| Depreciation and amortization | 1,160 | 925 |
| Noncash lease expense | 703 | 813 |
| Accretion of purchase discounts and amortization of premiums on investment securities, net | (2,220) | (4,376) |
| Loss on disposal of property and equipment | 20 | 19 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's stock-based comp?
- Crinetics Pharmaceuticals (CRNX) reported stock-based comp of $29.68M in Q1 2026.
- How has Crinetics Pharmaceuticals's stock-based comp changed year-over-year?
- Crinetics Pharmaceuticals's stock-based comp increased by 44.9% year-over-year, from $20.48M to $29.68M.
- What is the long-term trend for Crinetics Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's stock-based comp has grown at a 51.3% compound annual growth rate (CAGR), from $17.35M to $91.02M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Crinetics Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude